Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.63 |
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | HTR7 | P34969 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083785 | 0.86 | HRH3 (0.61) | HRH3SMN1; SMN2POLBSIGMAR1ACHE | |
| SCHEMBL19083896 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL4513928 | 0.83 | SMN1; SMN2 (0.65) | HRH3SMN1; SMN2POLBSIGMAR1KDM4E | |
| SCHEMBL3150313 | 0.83 | SMN1; SMN2 (0.65) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL15070467 | 0.83 | HTR7 (0.67) | HRH3SMN1; SMN2SIGMAR1ACHEHTR7 | |
| SCHEMBL19075637 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL4034625 | 0.83 | SIGMAR1 (0.60) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL156202 | 0.82 | HRH3 (0.76) | HRH3SIGMAR1ACHEKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL4036112 | 0.82 | SMN1; SMN2 (0.63) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL2214408 | 0.82 | SMN1; SMN2 (0.63) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | HRH3 1260/4885SMN1; SMN2 2803/4885POLB 2801/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | HRH3 16/4885SMN1; SMN2 3746/4885POLB 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.